ArticleBMJ global health2025
The economics of climate-sensitive infectious diseases affecting human health in Latin America and the Caribbean: a scoping review.
Article in BMJ global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- PulmonaromFrontiers in cellular and infection microbiology · 2026Article
- From spillover to systems: evidence gaps in One Health preparedness for emerging infectious diseases in Latin America and the Caribbean.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of climate-sensitive infectious diseases (CSIDs), such as dengue, chikungunya and Zika, has been rising in Latin America and the Caribbean (LAC). Reported cases of these diseases nearly doubled between 2022 and 2023, with the highest figure reported from Brazil. However, evidence regarding the economic cost of CSIDs is limited in the region. This scoping review aims to identify the available evidence on the economic impacts of CSIDs in LAC countries and the potential costs and benefits of adaptation interventions. We searched PubMed, the Virtual Health Library, Web of Science, Scopus, JSTOR and EconPapers and included peer-reviewed and grey-literature studies published between January 2015 and December 2023. 10 peer-reviewed studies were included in this review: 9 assessed the economic impacts of the health consequences of CSIDs and 1 assessed the economics of adaptation policies or programmes concerning human health in LAC countries. Most studies were conducted in Mexico and Brazil. Studies have focused primarily on the economic costs of arboviruses, influenza and enteritis. The outcomes most frequently studied were disability-adjusted life years and mortality. Only one study evaluated the economic impact of implementing an adaptation intervention for dengue. These findings highlight a significant gap in understanding the economic impacts of CSIDs, particularly because most studies fail to monetise the reported metrics, limiting their ability to provide a comprehensive assessment of economic costs and cost-effectiveness analyses of interventions. There is a need for further research in this field, incorporating data from a diverse range of countries in the region and analysing the economic impacts of various CSIDs, as well as the cost-effectiveness of interventions aimed at reducing their prevalence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.